Your session is about to expire
← Back to Search
Treatment for Stomach Cancer (CAMPERR Trial)
Summary
This is an observational case-control study to train and validate a genome-wide methylome enrichment platform to detect multiple cancer types and to differentiate amongst cancer types. The cancers included in this study are brain, breast, bladder, cervical, colorectal, endometrial, esophageal, gastric, head and neck, hepatobiliary, leukemia, lung, lymphoma, multiple myeloma, ovarian, pancreatic, prostate, renal, sarcoma, and thyroid. These cancers were selected based on their prevalence and mortality to maximize impact on clinical care. Additionally, the ability of the whole-genome methylome enrichment platform to detect minimal residual disease after completion of cancer treatment and to detect relapse prior to clinical presentation will be evaluated in four cancer types (breast, colorectal, lung, prostate). These cancers were selected based on the existing clinical landscape and treatment availability.
- Stomach Cancer
- Head and Neck Cancers
- Pancreatic Cancer
- Prostate Cancer
- Sarcoma
- Ovarian Cancer
- Colorectal Cancer
- Kidney Cancer
- Esophageal Cancer
- Breast Cancer
- Bladder Cancer
- Endometrial Cancer
- Thyroid Cancer
- Brain Metastases
- Cervical Cancer
- Liver Cancer
- Leukemia
- Lung Cancer
- Lymphoma
- Multiple Myeloma
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Find a Location
Who is running the clinical trial?
Share this study with friends
Copy Link
Messenger